Anthracyclines and Antitumor Antibiotics

Key Points

• Anthracyclines (for example doxorubicin, daunorubicin, epirubicin) inhibit topoisomerase to prevent DNA replication and trigger tumor-cell death.
• This class is a high-risk vesicant group; extravasation can cause severe tissue necrosis.
• Cumulative cardiotoxicity is a major dose-limiting toxicity; lifetime-dose limits and serial cardiac monitoring are required.
• Myelosuppression, nausea/vomiting, alopecia, and mucositis are common treatment-limiting adverse effects.
• Doxorubicin may cause temporary red-orange discoloration of urine and body fluids after treatment.

Mechanism of Action

Anthracyclines and related antitumor antibiotics interfere with DNA replication by inhibiting topoisomerase. This blocks DNA strand processing during cell division and promotes apoptosis in rapidly dividing tumor cells.

Common Drugs

• Doxorubicin
• Daunorubicin
• Epirubicin
• Bleomycin (classified as antitumor antibiotic and monitored for pulmonary toxicity risk)

Nursing Considerations

• Verify baseline and interval cardiac evaluation (including left ventricular ejection fraction) before and during anthracycline therapy.
• Track cumulative lifetime dosing, because heart-failure risk increases with repeat exposure (for example around 550 mg/m2 lifetime limits for doxorubicin/daunorubicin regimens).
• Monitor for early signs of cardiotoxicity: dyspnea, edema, fatigue, reduced activity tolerance, chest discomfort, and new rhythm concerns.
• Treat these agents as vesicants: confirm reliable vascular access, monitor site patency frequently, and follow immediate extravasation protocol if burning/swelling occurs.
• Assess CBC trends for myelosuppression and escalate neutropenic fever, bleeding cues, or symptomatic anemia promptly.
• Monitor for severe nausea/vomiting, mucositis, and cumulative organ toxicity patterns.

Adverse Effects and Contraindications

• Hematologic: myelosuppression, infection risk, bleeding risk.
• Cardiac: acute and delayed cardiotoxicity; risk increases with cumulative exposure.
• GI and mucosal: nausea/vomiting, stomatitis/mucositis.
• Dermatologic: alopecia, skin or nail hyperpigmentation.
• Pulmonary (selected agents such as bleomycin): interstitial injury/fibrosis risk.
• Contraindications include severe preexisting cardiac dysfunction and inadequate cardiac reserve for planned anthracycline exposure.

Health Teaching

• Report fever, sore throat, unusual bruising/bleeding, mouth ulcers, or persistent vomiting immediately.
• Report shortness of breath, chest pain, edema, or rapid unexplained weight gain promptly.
• Understand that temporary red-orange urine or body-fluid discoloration after doxorubicin can occur.
• Avoid pregnancy during therapy and follow contraception guidance from the oncology team.
• Keep all scheduled lab and cardiac follow-up appointments.

Related Concepts

• vesicants - Class-level extravasation injury risk and antidote pathways.
• infiltration-and-extravasation - Immediate bedside response steps for suspected leakage.
• medication-induced-cardiopulmonary-adverse-effects - Cumulative cardiotoxic monitoring framework.
• leukopenia-and-neutropenia - Infection-risk escalation during marrow suppression.
• thrombocytopenia-bleeding-risk-and-management - Bleeding-risk surveillance in cytopenic phases.

Self-Check

1. Why is cumulative-dose tracking required for anthracycline therapy?
2. What bedside findings should trigger immediate extravasation response during infusion?
3. Which symptoms require urgent escalation for potential anthracycline cardiotoxicity?